- Noramco at DCAT Week 2019
- Say Hello to Dan Hallow
- Say Hello to Nancy Bye
- Noramco at AAPS 2018
- Noramco Adds Capacity and Dual Sources of Supply for Cannabinoids
- Noramco Announces Provisional Patent Application of Proprietary Cannabidiol (CBD)
- Say Hello to Pete Lantagne
- A Winning United Way Campaign
- Say Hello to Divya Tewari
- Noramco at CPhI 2018
- Say Hello to Zenia Chalupa
- AXIM Biotechnologies Advances Dronabinol Therapeutic Equivalence Program Through Purchase Agreement With Noramco
- Noramco Competes in 10th Consecutive American Odyssey Relay Run for Charity
- Say Hello to Justin Mills
- Noramco and SPI Pharma sign agreement to develop ready-to-implement, patient-friendly formulations for pharmaceutical manufacturers
The Noramco Difference
Pharmaceutical companies trust Noramco to produce ultra-pure synthetic cannabinoid active ingredients that meet the strictest regulatory requirements of health authorities around the world. High capacity cGMP production facilities in Europe and the United States yield ultra-pure Cannabidiol (CBD), Dronabinol (THC), and Nabilone active ingredients.
For more than a decade Noramco has consistently delivered large volumes of Nal-family compounds and Buprenorphine HCI to the pharmaceutical industry. Noramco has made a long-term commitment to antagonist APIs, providing both the technologies and expertise pharmaceutical companies require to produce and commercialize addiction treatment and abuse prevention products (ATAP).
ADHD API Portfolio
Building out our ADHD capability for customers that want to work with us strategically throughout the ADHD range of technology, Noramco now offers a full range of APIs. ADHD focus products, an area which leverages our controlled substance expertise, and over a decade of supply, is an increasingly important technology platform within Noramco. Customers may call on us for high-quality Methylphenidate HCl, DexMethylphenidate, and Amphetamine Salts.